Ocular Therapeutix: Bollinger Bands Narrowing, KDJ Death Cross on 15min Chart

According to the 15-minute chart for Ocular Therapeutix, the recent activity has triggered a narrowing of Bollinger Bands and a KDJ Death Cross, which occurred on August 18, 2025 at 15:45. This suggests that the magnitude of price fluctuations is decreasing, and the momentum of the stock price is shifting towards the downside, with potential for further decreases.

Ocular Therapeutix, Inc. (NASDAQ: OCUL), an integrated biopharmaceutical company focused on redefining the retina experience, has recently received a significant regulatory milestone. The company announced on August 12, 2025, that it has secured a written agreement regarding a registrational trial design from the U.S. Food and Drug Administration (FDA) under a Special Protocol Assessment (SPA) for its planned clinical trial of AXPAXLI (also known as OTX-TKI) for the treatment of non-proliferative diabetic retinopathy (NPDR) [1].

However, recent technical indicators have raised concerns among investors. According to the 15-minute chart for Ocular Therapeutix, the stock experienced a narrowing of Bollinger Bands and a KDJ Death Cross, which occurred on August 18, 2025, at 15:45. This suggests that the magnitude of price fluctuations is decreasing, and the momentum of the stock price is shifting towards the downside, with potential for further decreases [2].

Despite the technical challenges, Ocular Therapeutix continues to make strides in its pipeline. The company's investigational product candidate AXPAXLI is an axitinib intravitreal hydrogel based on its ELUTYX proprietary bioresorbable hydrogel-based formulation technology. AXPAXLI is currently in Phase 3 clinical trials for wet age-related macular degeneration (wet AMD) [1].

Ocular Therapeutix is scheduled to review its strategy and the next steps for AXPAXLI in NPDR and DME at its upcoming Investor Day on September 30, 2025. The event will be held in New York City and will provide investors with an opportunity to gain more insights into the company's plans [1].

References:
[1] https://www.globenewswire.com/fr/news-release/2025/08/12/3131550/0/en/Ocular-Therapeutix-Receives-FDA-Agreement-Under-Special-Protocol-Assessment-SPA-for-Registrational-Trial-of-AXPAXLI-in-NPDR.html
[2] https://www.ainvest.com/news/4d-molecular-15min-chart-overbought-rsi-kdj-death-cross-triggered-2508-37/